Pure Global
NCT06048536

Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch

An Open-label, Phase II, Dose-finding Study of Three Dose Strengths of MR-130A-01 Contraceptive Transdermal Patch in Healthy Pre-menopausal Women
Viatris Inc.·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Contraception
Drug/Device/Intervention
MR-130A-01 Transdermal patch
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Viatris Inc.
Location
Berlin, Germany
Timeline & enrollment
Phase
Phase 2
Start date
Mar 07, 2023
End date
Dec 31, 2023
Enrollment
168 participants
Primary outcome

Proportion of responder overall (subjects with no ovulation in both treatment cycles),Proportion of responder in cycle (subjects with no ovulation in one of the treatment cycles)

Summary

A single-center, randomized, open-label, parallel-group, multi-arm, phase II clinical trial
 in healthy women aged 18 to 35 years who have a documented ovulatory cycle prior to
 randomization.

ICD-10 classifications
Contraceptive managementOral contraceptivesOther contraceptive managementGeneral counselling and advice on contraceptionPersonal history of contraception
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06048536
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06048536 through Pure Global AI's free database. This Phase 2 trial is sponsored by Viatris Inc. and is currently Recruiting. The study focuses on Contraception. Target enrollment is 168 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.